Compare Stocks → Did you make $29,000 two days with AI options trades? (From Prosper Trading Academy) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ACRSNASDAQ:ARQTNASDAQ:CARANASDAQ:STTKNASDAQ:TBPH Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$1.24-1.6%$1.21$0.59▼$11.12$87.95M0.211.75 million shs598,346 shsARQTArcutis Biotherapeutics$9.91+3.3%$8.26$1.76▼$15.40$959.39M1.155.18 million shs3.72 million shsCARACara Therapeutics$0.91+4.6%$0.73$0.50▼$5.20$49.74M0.7736,299 shs637,269 shsSTTKShattuck Labs$8.94-0.4%$9.25$1.33▼$11.11$424.38M2.12389,000 shs319,072 shsTBPHTheravance Biopharma$8.97-0.4%$9.01$8.21▼$12.03$432.09M0.36369,312 shs401,710 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics+6.78%+5.88%+4.13%+17.76%-84.33%ARQTArcutis Biotherapeutics+3.45%-11.20%-1.03%+190.61%-6.35%CARACara Therapeutics+19.01%-3.74%+8.48%+13.27%-82.41%STTKShattuck Labs+1.47%-5.17%-6.46%+24.03%+195.39%TBPHTheravance Biopharma+2.15%0.00%-2.38%-20.34%-14.84%Did you make $29,000 two days with AI options trades? (Ad)What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:Click Here To Get Your Free CopyMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACRSAclaris Therapeutics2.9592 of 5 stars3.14.00.00.03.21.71.3ARQTArcutis Biotherapeutics2.761 of 5 stars3.44.00.00.02.12.50.6CARACara Therapeutics4.5288 of 5 stars3.42.00.04.24.41.71.3STTKShattuck Labs2.2026 of 5 stars3.53.00.00.03.31.70.0TBPHTheravance Biopharma1.9096 of 5 stars3.51.00.00.02.42.50.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRSAclaris Therapeutics2.14Hold$22.251,694.35% UpsideARQTArcutis Biotherapeutics2.78Moderate Buy$26.56167.97% UpsideCARACara Therapeutics2.75Moderate Buy$9.75971.43% UpsideSTTKShattuck Labs3.00Buy$20.00123.71% UpsideTBPHTheravance Biopharma3.00Buy$20.00122.97% UpsideCurrent Analyst RatingsLatest ACRS, CARA, ARQT, TBPH, and STTK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/6/2024CARACara TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.003/5/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/1/2024STTKShattuck LabsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.003/1/2024STTKShattuck LabsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.002/28/2024ARQTArcutis BiotherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$6.00 ➝ $11.002/28/2024ARQTArcutis BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.00 ➝ $16.002/23/2024ARQTArcutis BiotherapeuticsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $16.002/13/2024STTKShattuck LabsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.002/13/2024STTKShattuck LabsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.001/22/2024ACRSAclaris TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRSAclaris Therapeutics$31.25M2.81N/AN/A$2.22 per share0.56ARQTArcutis Biotherapeutics$59.61M16.09N/AN/A$0.94 per share10.54CARACara Therapeutics$20.97M2.37N/AN/A$1.05 per share0.87STTKShattuck Labs$1.66M255.65N/AN/A$3.41 per share2.62TBPHTheravance Biopharma$57.42M7.52N/AN/A$4.28 per share2.10Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRSAclaris Therapeutics-$88.48M-$1.27N/AN/AN/A-283.15%-64.56%-49.10%5/13/2024 (Estimated)ARQTArcutis Biotherapeutics-$262.14M-$3.92N/AN/AN/A-439.79%-294.85%-78.57%5/14/2024 (Estimated)CARACara Therapeutics-$118.51M-$2.18N/AN/AN/A-565.21%-122.10%-89.64%5/20/2024 (Estimated)STTKShattuck Labs-$87.30M-$2.05N/AN/AN/A-5,268.44%-63.08%-56.05%5/14/2024 (Estimated)TBPHTheravance Biopharma-$55.19M-$0.97N/AN/AN/A-96.12%-19.31%-12.03%5/13/2024 (Estimated)Latest ACRS, CARA, ARQT, TBPH, and STTK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/4/202412/31/2023CARACara Therapeutics-$0.57-$0.59-$0.02-$0.59$2.34 million$3.00 million 2/29/2024Q4 2023STTKShattuck Labs-$0.51-$0.41+$0.10-$0.41$0.50 million$0.71 million2/27/2024Q4 2023ACRSAclaris Therapeutics-$0.37-$0.30+$0.07-$0.58$3.96 million$17.57 million2/27/202412/31/2023ARQTArcutis Biotherapeutics-$0.64-$0.72-$0.08-$0.72$11.78 million$13.53 million 2/26/2024Q4 2023TBPHTheravance Biopharma-$0.15-$0.17-$0.02-$0.17$17.49 million$17.57 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRSAclaris TherapeuticsN/AN/AN/AN/AN/AARQTArcutis BiotherapeuticsN/AN/AN/AN/AN/ACARACara TherapeuticsN/AN/AN/AN/AN/ASTTKShattuck LabsN/AN/AN/AN/AN/ATBPHTheravance BiopharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRSAclaris TherapeuticsN/A4.164.16ARQTArcutis Biotherapeutics2.287.086.80CARACara TherapeuticsN/A4.544.43STTKShattuck LabsN/A12.5112.51TBPHTheravance BiopharmaN/A5.395.39OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRSAclaris Therapeutics98.34%ARQTArcutis BiotherapeuticsN/ACARACara Therapeutics44.66%STTKShattuck Labs58.74%TBPHTheravance Biopharma99.10%Insider OwnershipCompanyInsider OwnershipACRSAclaris Therapeutics5.50%ARQTArcutis Biotherapeutics20.70%CARACara Therapeutics4.20%STTKShattuck Labs9.89%TBPHTheravance Biopharma5.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableACRSAclaris Therapeutics8670.93 million67.02 millionOptionableARQTArcutis Biotherapeutics29696.81 million76.77 millionOptionableCARACara Therapeutics5554.66 million52.36 millionOptionableSTTKShattuck Labs7547.47 million42.78 millionOptionableTBPHTheravance Biopharma35948.17 million45.61 millionOptionableACRS, CARA, ARQT, TBPH, and STTK HeadlinesSourceHeadlineWhy Is Theravance Bio (TBPH) Down 9% Since Last Earnings Report?zacks.com - March 27 at 12:36 PMTheravance Biopharma (NASDAQ:TBPH) Shares Cross Below 50-Day Moving Average of $9.04americanbankingnews.com - March 26 at 5:14 AMTheravance Biopharma (NASDAQ:TBPH) Stock Price Crosses Below Fifty Day Moving Average of $9.04marketbeat.com - March 26 at 5:14 AMZacks Research Weighs in on Theravance Biopharma, Inc.'s Q1 2024 Earnings (NASDAQ:TBPH)americanbankingnews.com - March 18 at 1:28 AMEquities Analysts Offer Predictions for Theravance Biopharma, Inc.'s Q1 2024 Earnings (NASDAQ:TBPH)marketbeat.com - March 18 at 1:27 AMTheravance Biopharma, Inc. (NASDAQ:TBPH) Forecasted to Earn FY2026 Earnings of $0.75 Per Sharemarketbeat.com - March 15 at 7:48 AMJacobs Levy Equity Management Inc. Has $3.52 Million Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH)marketbeat.com - March 15 at 4:15 AMShort-Squeeze Showdown: 3 Stocks Ready to Crush the Skepticsinvestorplace.com - March 12 at 3:59 PMTheravance Biopharma, Inc. (NASDAQ:TBPH) Forecasted to Earn Q1 2024 Earnings of ($0.40) Per Sharemarketbeat.com - March 8 at 6:18 AMAnalyst Reiterates Buy Rating with Increased Price Target Amidst Financial Adjustments and Milestone Payment Potentialmarkets.businessinsider.com - March 7 at 9:55 AMFY2026 EPS Estimates for Theravance Biopharma, Inc. Raised by Leerink Partnrs (NASDAQ:TBPH)marketbeat.com - March 7 at 7:53 AMTheravance Biopharma: A Strong Buy on Underappreciated Cash Flow Potential and Strategic Milestonesmarkets.businessinsider.com - February 28 at 10:50 AMTheravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - February 28 at 10:50 AMTheravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updatestockhouse.com - February 27 at 11:30 PMTheravance Biopharma Inc (TBPH)investing.com - February 27 at 1:29 PMTheravance's (TBPH) Q4 Earnings & Revenues Surpass Estimateszacks.com - February 27 at 12:51 PMBalancing Growth Prospects and Clinical Outcomes: Hold Rating on Theravance Biopharmamarkets.businessinsider.com - February 27 at 1:45 AMTheravance Biopharma GAAP EPS of -$0.17 misses by $0.02, revenue of $17.6M beats by $0.03Mmsn.com - February 26 at 8:44 PMTheravance Biopharma (TBPH) Tops Q4 Earnings and Revenue Estimateszacks.com - February 26 at 6:26 PMTheravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updateprnewswire.com - February 26 at 4:05 PMTheravance Biopharma Q4 2023 Earnings Previewseekingalpha.com - February 25 at 6:21 PMTheravance Biopharma Stock (NASDAQ:TBPH) Dividends: History, Yield and Datesbenzinga.com - February 24 at 9:19 AMTheravance Biopharma (TBPH) Price Target Increased by 5.77% to 14.03msn.com - February 24 at 9:19 AMTheravance Biopharma to Participate in an Upcoming Investor Conferenceprnewswire.com - February 22 at 6:00 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAclaris TherapeuticsNASDAQ:ACRSAclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Arcutis BiotherapeuticsNASDAQ:ARQTArcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Cara TherapeuticsNASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.Shattuck LabsNASDAQ:STTKShattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.Theravance BiopharmaNASDAQ:TBPHTheravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.